255 related articles for article (PubMed ID: 30878213)
1. Calcimimetics maintain bone turnover in uremic rats despite the concomitant decrease in parathyroid hormone concentration.
Díaz-Tocados JM; Rodríguez-Ortiz ME; Almadén Y; Pineda C; Martínez-Moreno JM; Herencia C; Vergara N; Pendón-Ruiz de Mier MV; Santamaría R; Rodelo-Haad C; Casado-Díaz A; Lorenzo V; Carvalho C; Frazão JM; Felsenfeld AJ; Richards WG; Aguilera-Tejero E; Rodríguez M; López I; Muñoz-Castañeda JR
Kidney Int; 2019 May; 95(5):1064-1078. PubMed ID: 30878213
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a calcimimetic with differential effects on parathyroid hormone and calcitonin secretion.
Henley C; Yang Y; Davis J; Lu JY; Morony S; Fan W; Florio M; Sun B; Shatzen E; Pretorius JK; Richards WG; St Jean DJ; Fotsch C; Reagan JD
J Pharmacol Exp Ther; 2011 Jun; 337(3):681-91. PubMed ID: 21422163
[TBL] [Abstract][Full Text] [Related]
3. Comparative effects of calcitriol and calcimimetic on bone health in renal insufficiency.
Díaz-Tocados JM; Rodríguez-Ortiz ME; Herencia C; López-Baltanás R; Jurado-Montoya D; García-Saez RM; Valdés-Díaz K; Martínez-Moreno JM; Santamaría R; Pendón-Ruiz de Mier MV; Rodelo-Haad C; Frazão JM; Felsenfeld AJ; Rodríguez M; Almadén Y; Muñoz-Castañeda JR
FASEB J; 2024 Jun; 38(11):e23726. PubMed ID: 38847773
[TBL] [Abstract][Full Text] [Related]
4. Calcimimetics normalize the phosphate-induced stimulation of PTH secretion in vivo and in vitro.
Almaden Y; Rodriguez-Ortiz ME; Canalejo A; Cañadillas S; Canalejo R; Martin D; Aguilera-Tejero E; Rodríguez M
J Nephrol; 2009; 22(2):281-8. PubMed ID: 19384847
[TBL] [Abstract][Full Text] [Related]
5. Calcimimetic agents: review and perspectives.
Ureña P; Frazão JM
Kidney Int Suppl; 2003 Jun; (85):S91-6. PubMed ID: 12753275
[TBL] [Abstract][Full Text] [Related]
6. Functional proteins involved in regulation of intracellular Ca(2+) for drug development: the extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimetics.
Nagano N; Nemeth EF
J Pharmacol Sci; 2005 Mar; 97(3):355-60. PubMed ID: 15781990
[TBL] [Abstract][Full Text] [Related]
7. Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia.
Ishii H; Wada M; Furuya Y; Nagano N; Nemeth EF; Fox J
Bone; 2000 Feb; 26(2):175-82. PubMed ID: 10678413
[TBL] [Abstract][Full Text] [Related]
8. Prevention of uremic bone disease using calcimimetic compounds.
Olgaard K; Lewin E
Annu Rev Med; 2001; 52():203-20. PubMed ID: 11160775
[TBL] [Abstract][Full Text] [Related]
9. [Calcimimetics].
Messa P; Como G; Brezzi B
G Ital Nefrol; 2006; 23(1):12-21. PubMed ID: 16521071
[TBL] [Abstract][Full Text] [Related]
10. [Calcimimetics, mechanisms of action and therapeutic applications].
Ureña P; Legoupil N; de Vernejoul MC
Presse Med; 2005 Sep; 34(15):1095-100. PubMed ID: 16334889
[TBL] [Abstract][Full Text] [Related]
11. The calcimimetic AMG 641 abrogates parathyroid hyperplasia, bone and vascular calcification abnormalities in uremic rats.
Henley C; Davis J; Miller G; Shatzen E; Cattley R; Li X; Martin D; Yao W; Lane N; Shalhoub V
Eur J Pharmacol; 2009 Aug; 616(1-3):306-13. PubMed ID: 19470383
[TBL] [Abstract][Full Text] [Related]
12. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
13. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease.
Quarles LD; Sherrard DJ; Adler S; Rosansky SJ; McCary LC; Liu W; Turner SA; Bushinsky DA
J Am Soc Nephrol; 2003 Mar; 14(3):575-83. PubMed ID: 12595492
[TBL] [Abstract][Full Text] [Related]
14. [Calcimimetic agents in the treatment of hyperparathyroidism secondary to chronic renal failure].
Negri AL; Slatopolsky EA
Medicina (B Aires); 2003; 63(2):165-71. PubMed ID: 12793088
[TBL] [Abstract][Full Text] [Related]
15. [Parathyroid and bone. Calcimimetics and bone metabolism].
Fukumoto S
Clin Calcium; 2007 Dec; 17(12):1865-9. PubMed ID: 18057662
[TBL] [Abstract][Full Text] [Related]
16. Recent updates on the calcium-sensing receptor as a drug target.
Trivedi R; Mithal A; Chattopadhyay N
Curr Med Chem; 2008; 15(2):178-86. PubMed ID: 18220773
[TBL] [Abstract][Full Text] [Related]
17. The Use of Calcimimetics for the Treatment of Secondary Hyperparathyroidism: A 10 Year Evidence Review.
Rodríguez M; Goodman WG; Liakopoulos V; Messa P; Wiecek A; Cunningham J
Semin Dial; 2015; 28(5):497-507. PubMed ID: 25752650
[TBL] [Abstract][Full Text] [Related]
18. Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency.
Mizobuchi M; Hatamura I; Ogata H; Saji F; Uda S; Shiizaki K; Sakaguchi T; Negi S; Kinugasa E; Koshikawa S; Akizawa T
J Am Soc Nephrol; 2004 Oct; 15(10):2579-87. PubMed ID: 15466262
[TBL] [Abstract][Full Text] [Related]
19. Calcimimetics increase CaSR expression and reduce mineralization in vascular smooth muscle cells: mechanisms of action.
Hénaut L; Boudot C; Massy ZA; Lopez-Fernandez I; Dupont S; Mary A; Drüeke TB; Kamel S; Brazier M; Mentaverri R
Cardiovasc Res; 2014 Feb; 101(2):256-65. PubMed ID: 24217682
[TBL] [Abstract][Full Text] [Related]
20. Calcimimetic and calcilytic drugs for treating bone and mineral-related disorders.
Nemeth EF; Shoback D
Best Pract Res Clin Endocrinol Metab; 2013 Jun; 27(3):373-84. PubMed ID: 23856266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]